The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

The multicenter study randomized 196 patients with poorly controlled asthma despite moderate to high doses of inhaled corticosteroid and long-acting β2 adrenergic agonist (ICS/LABA) treatment.

Indications are restrictive and reflect the inclusion criteria of the INNOVATE trial, which enrolled individuals with asthma taking high-dose ICS + LABA and additional controller medications.

Previous guidelines recommended the use of maintenance inhalers such as those that combine ICS and a long-acting beta agonist (LABA), generally used twice a day, in addition to short-acting rescue ...

a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer comparable or incremental ...